US4256748A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Imidazo[2,1-b]quinazolin-2(3H)-ones and pharmaceutical compositions for treatment and prophylaxis of cardiac insufficiency and cardiac failure
Assignee: Hoffmann La Roche Inc
•
Filing: 1979-06-20
•
Granted: 1981-03-17
•
Expires: 1999-06-20
Abstract
Abstract Compounds of the formula <IMAGE> I wherein R1,R2,R3 and R4 are as hereinafter described, tautomers and salts thereof, are disclosed. The foregoing compounds inhibit the aggregation of blood platelets which renders them useful as therapeutic agents in the prophylaxis of thromboses. Furthermore, they are useful for the treatment and prophylaxis of cardiac insufficiency and cardiac failure, due to their inotropic activity without substantial tachycardia.
Inventors
- 👤 Madhukar S. Chodnekar
- 👤 Ado Kaiser
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 17:46
CPC Classifications
C; C07; C07D; C07D487/00; C07D487/02; C07D487/04; A; A61; A61P; A61P7/00; A61P7/02; A61P9/00; A61P9/04
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
24 words
A compound of the group consisting of D-6-chloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-7-bromo-1,5-dihydro-3,6-dimethyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-6-chloro-1,5-dihydro-7-methoxy-3-methyl-imidazo[2,1-b]quinazolin-2-(3H)-one; D-6,7-dichloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-7-bromo-6-chloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-3,6-dimethyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2-(3H)-one; L-3,6-dimethyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2(3H)-one; L-3,9-dimethyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2(3H)-one; D-7-bromo-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazoline-2(3H)-one, their tautomers and pharmaceutically acceptable acid addition salts.
Claim 2
Dependent Claim
24 words
A compound of the group consisting of D-6-chloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-7-bromo-1,5-dihydro-3,6-dimethyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-6-chloro-1,5-dihydro-7-methoxy-3-methyl-imidazo[2,1-b]quinazolin-2-(3H)-one; D-6,7-dichloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-7-bromo-6-chloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-3,6-dimethyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2-(3H)-one; L-3,6-dimethyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2(3H)-one; L-3,9-dimethyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2(3H)-one; D-7-bromo-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazoline-2(3H)-one, their tautomers and pharmaceutically acceptable acid addition salts.
Claim 3
Dependent Claim
16 words
A compound in accordance with claim 1, D-6-chloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one or a pharmaceutically acceptable acid addition salt thereof.
Claim 4
Dependent Claim
14 words
A compound in accordance with claim 1, L-1,5-dihydro-3,9-dimethylimidazo-[2,1-b]quinazolin-2(3H)-one or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
14 words
A compound in accordance with claim 1, D-1,5-dihydro-3,6-dimethyl-imidazo[2,1-b]quinazolin-2(3H)-one or a pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
14 words
A compound in accordance with claim 1, L-1,5-dihydro-3,6-dimethyl-imidazo[2,1-b]quinazolin-2(3H)-one or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
14 words
A compound in accordance with claim 1, D-6-chloro-1,5-dihydro-3-methyl-7-methoxy-imidazo[2,1-b]quinazolin-2(3H)-one or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
14 words
A compound in accordance with claim 1, D-7-bromo-6-chloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim
14 words
A compound in accordance with claim 1, D-7-bromo-1,5-dihydro-3-methyl-imidazo[,1-b]quinazolin-2(3H)-one or a pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim
14 words
A compound in accordance with claim 1, D-6,7-dichloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
14 words
A compound in accordance with claim 1, D-7-bromo-1,5-dihydro-3,6-dimethyl-imidazo[2,1-b]quinazolin-2(3H)-one or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim
56 words
A pharmaceutical composition for the treatment and prophylaxis of cardiac insufficiency and cardiac failure containing an effective amount for such treatment and prophylaxis of a compound of the group consisting of D-6-chloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-7-bromo-1,5-dihydro-3,6-dimethyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-6-chloro-1,5-dihydro-7-methoxy-3-methyl-imidazo[2,1-b]quinazolin-2-(3H)-one; D-6,7-dichloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-7-bromo-6-chloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-3,6-dimethyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2(3H)-one; L-3,6-dimethyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2(3H)-one; L-3,9-dimethyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2(3H)-one; D-7-bromo-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazoline-2(3H)-one, their tautomers and pharmaceutically acceptable acid addition salts in association with a compatible pharmaceutical carrier material.
Claim 13
Dependent Claim
56 words
A pharmaceutical composition for the treatment and prophylaxis of cardiac insufficiency and cardiac failure containing an effective amount for such treatment and prophylaxis of a compound of the group consisting of D-6-chloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-7-bromo-1,5-dihydro-3,6-dimethyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-6-chloro-1,5-dihydro-7-methoxy-3-methyl-imidazo[2,1-b]quinazolin-2-(3H)-one; D-6,7-dichloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-7-bromo-6-chloro-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one; D-3,6-dimethyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2(3H)-one; L-3,6-dimethyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2(3H)-one; L-3,9-dimethyl-1,5-dihydro-imidazo[2,1-b]quinazolin-2(3H)-one; D-7-bromo-1,5-dihydro-3-methyl-imidazo[2,1-b]quinazoline-2(3H)-one, their tautomers and pharmaceutically acceptable acid addition salts in association with a compatible pharmaceutical carrier material.
References Cited (Backward Citations)
GB1067745A
Cited
GB1037375A
Cited
DE2305575A1
Cited
GB1418822A
Cited
US3932407A
Cited
US3983119A
Cited
US3988340A
Cited
GB2001638A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-03-16 | 1984-09-15 | 1985-03-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-03-16 | 1988-09-15 | 1989-03-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-03-16 | 1992-09-15 | 1993-03-17 | $7700.00 | Window Closed / Lapsed |